Bioresorbable Vascular Scaffolds for Coronary Revascularization

Circulation

Volumn 134, Issue 2, 2016, Pages 168-182

  Kereiakes, Dean J ^a   Onuma, Yoshinobu ^b   Serruys, Patrick W ^c   Stone, Gregg W ^d  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

angioplasty; revascularization; stents

Indexed keywords

MAGNESIUM; POLYLACTIC ACID; ALLOY;

ARTICLE; BARE METAL STENT; BIOLIMUS ELUTING CORONARY STENT; BIORESORBABLE SCAFFOLD; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HUMAN; LONG TERM CARE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; ADVERSE EFFECTS; ANIMAL; BIODEGRADABLE IMPLANT; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG ELUTING STENT; EQUIPMENT DESIGN; MINIPIG; OPTICAL COHERENCE TOMOGRAPHY; PIG; ST ELEVATION MYOCARDIAL INFARCTION; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; ALLOYS; ANIMALS; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FOLLOW-UP STUDIES; HUMANS; MAGNESIUM; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ST ELEVATION MYOCARDIAL INFARCTION; SWINE; SWINE, MINIATURE; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84978374685     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.021539     Document Type: Article

References (57)

1. Windecker S, Stortecky S, Stefanini GG, da Costa BR, daCosta BR, Rutjes AW, Di Nisio M, Silletta MG, Siletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Jüni P, Juni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859.
2. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-2891. doi: 10.1161/CIRCULATIONAHA.112.097014.
3. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496-2507. doi: 10.1016/j.jacc.2015.04.017.
4. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R. Pathology of second-generation everolimus-eluting stents versus firstgeneration sirolimus-and paclitaxel-eluting stents in humans. Circulation. 2014;129:211-223. doi: 10.1161/CIRCULATIONAHA. 113.001790.
5. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S. Comparison of zotarolimus-and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e002230. doi: 10.1161/CIRCINTERVENTIONS. 114.002230.
6. Yamaji K, Kimura T, Morimoto T, Nakagawa Y, Inoue K, Soga Y, Arita T, Shirai S, Ando K, Kondo K, Sakai K, Goya M, Iwabuchi M, Yokoi H, Nosaka H, Nobuyoshi M. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv. 2010;3:468-475. doi: 10.1161/CIRCINTERVENTIONS.110.958249.
7. Vert M. Bioabsorbable polymers in medicine: an overview. EuroIntervention. 2009;5(suppl F):F9-F14. doi: 10.4244/EIJV5IFA2.
8. Hikita H, Sato A, Nozato T, Kawashima T, Takahashi Y, Kuwahara T, Takahashi A. Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation. Scand Cardiovasc J. 2009;43:298-303. doi: 10.1080/14017430902785493.
9. Gomez-Lara J, Brugaletta S, Farooq V, van Geuns RJ, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Morel MA, Dorange C, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv. 2011;4:789-799. doi: 10.1016/j.jcin.2011.04.009.
10. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43-54. doi: 10.1016/S0140-6736(14)61455-0.
11. Kuramitsu S, Iwabuchi M, Haraguchi T, Domei T, Nagae A, Hyodo M, Yamaji K, Soga Y, Arita T, Shirai S, Kondo K, Ando K, Sakai K, Goya M, Takabatake Y, Sonoda S, Yokoi H, Toyota F, Nosaka H, Nobuyoshi M. Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv. 2012;5:663-671. doi: 10.1161/CIRCINTERVENTIONS.112.969238.
12. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. Euro-Intervention. 2009;5(suppl F):F15-F22. doi: 10.4244/EIJV5IFA3.
13. Persaud-Sharma D, McGoron A. Biodegradable magnesium alloys: a review of material development and applications. J Biomim Biomater Tissue Eng. 2012;12:25-39. doi: 10.4028/www.scientific.net/JBBTE.12.25.
14. Lane JP, Perkins LE, Sheehy AJ, Pacheco EJ, Frie MP, Lambert BJ, Rapoza RJ, Virmani R. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv. 2014;7:688-695. doi: 10.1016/j.jcin.2013.11.024.
15. Tanaka A, Ruparelia N, Kawamoto H, Latib A, Colombo A. Positive vessel remodeling and appearance of pulsatile wall motion at long-term follow-up after bioresorbable scaffold implantation in a chronic total occlusion. JACC Cardiovasc Interv. 2015;8:1635-1637. doi: 10.1016/j.jcin.2015.06.022.
16. Gupta V, Grande-Allen KJ. Effects of static and cyclic loading in regulating extracellular matrix synthesis by cardiovascular cells. Cardiovasc Res. 2006;72:375-383. doi: 10.1016/j.cardiores. 2006.08.017.
17. Huang AH, Farrell MJ, Kim M, Mauck RL. Long-term dynamic loading improves the mechanical properties of chondrogenic mesenchymal stem cell-laden hydrogel. Eur Cell Mater. 2010;19:72-85.
18. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9:1271-1284. doi: 10.4244/EIJV9I11A217.
19. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Lim ST, Escaned J, Garcia-Garcia HM, Waksman R. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, nonrandomised, first-in-man trial. Lancet. 2016;387:31-39. doi: 10.1016/S0140-6736(15)00447-X.
20. Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Chevalier B, Smits P, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Wasungu L, Ediebah D, Veldhof S, Onuma Y. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J Am Coll Cardiol. 2016;67:766-776. doi: 10.1016/j.jacc.2015.11.060.
21. Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330-342. doi: 10.1161/CIRCINTERVENTIONS.113.000990.
22. Karanasos A, Simsek C, Gnanadesigan M, Van Ditzhuijzen NS, Freire R, Dijkstra J, Tu S, Van Mieghem N, Van Soest G, de Jaegere P, Serruys PW, Zijlstra F, Van Geuns RJ, Regar E. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64:2343-2356. doi: 10.1016/j. jacc.2014.09.029.
23. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, Van Geuns RJ, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, Ormiston J, Serruys PW. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221:106-112. doi: 10.1016/j.atherosclerosis. 2011.12.008.
24. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49:706-715. doi: 10.1016/j. jacc.2006.09.047.
25. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138-1145. doi: 10.1161/CIRCULATIONAHA.107.762047.
26. Kereiakes DJ, Ellis SG, Popma JJ, Fitzgerald PJ, Samady H, Jones-McMeans J, Zhang Z, Cheong WF, Su X, Ben-Yehuda O, Stone GW. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J. 2015;170:641-651.e3. doi: 10.1016/j.ahj.2015.07.013.
27. Rizik DG, Cannon L, Stone GW, Kennedy M, Piard-Ruster K, Staehr P, Ellis SG, Kereiakes DJ. Systemic pharmacokinetics of everolimus eluted from the absorb bioresorbable vascular scaffold: an ABSORB III substudy. J Am Coll Cardiol. 2015;66:2467-2469. doi: 10.1016/j.jacc.2015.09.030.
28. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779-797. doi: 10.1161/CIRCULATIONAHA. 110.971606.
29. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791-801. doi: 10.1016/j.jacc.2014.12.017.
30. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H, Stone GW; ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332-3342. doi: 10.1093/eurheartj/ehv435.
31. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW; ABSORB China Investigators. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol. 2015;66:2298-2309. doi: 10.1016/j.jacc.2015.09.054.
32. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905-1915. doi: 10.1056/NEJMoa1509038.
33. Danzi GB, Sesana M, Arieti M, Villa G, Rutigliano S, Aprile A, Nicolino A, Moshiri S, Valenti R. Does optimal lesion preparation reduce the amount of acute recoil of the Absorbe BVS? Insights from a real-world population. Catheter Cardiovasc Interv. 2015;86:984-991. doi: 10.1002/ccd.26148.
34. Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW. 1-Year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled metaanalysis. Lancet. 2016;387:1277-1289. doi: 10.1016/S0140-6736(15)01039-9.
35. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144-1153. doi: 10.4244/EIJY14M07-11.
36. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T, Kastrati A. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387:537-544. doi: 10.1016/S0140-6736(15)00979-4.
37. Byrne RA, Kastrati A. Bioresorbable drug-eluting stents: an immature technology in need of mature application. JACC Cardiovasc Interv. 2015;8(pt B):198-200. doi: 10.1016/j.jcin.2014.11.010.
38. Lipinski MJ, Escarcega RO, Baker NC, Benn HA, Gaglia MA Jr, Torguson R, Waksman R. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2016;9:12-24. doi: 10.1016/j.jcin.2015.09.024.
39. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-1409. doi: 10.1161/CIRCULATIONAHA.110.003210.
40. Gori T, Schulz E, Münzel T. Immediate, acute, and subacute thrombosis due to incomplete expansion of bioresorbable scaffolds. JACC Cardiovasc Interv. 2014;7:1194-1195. doi: 10.1016/j. jcin.2014.07.004.
41. Onuma Y, Serruys PW, Muramatsu T, Nakatani S, Van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014;7:1400-1411. doi: 10.1016/j.jcin.2014.06.016.
42. Stone GW, Ellis SG, Simonton C, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Popma JJ, McGreevy R, Zhang Z, Kereiakes DJ. Outcomes of the ABSORB bioresorbable vascular scaffold in very small and not very small coronary arteries: the ABSORB III randomized trial. J Am Coll Cardiol. 2016;67(suppl):35.
43. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, Binder H, Eggebrecht H, Münzel T, Cook S, Gori T. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921-931. doi: 10.1016/j. jacc.2015.12.019.
44. Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, Bartorelli AL, Whitbourn R, Chevalier B, Abizaid A, Ormiston JA, Rapoza RJ, Veldhof S, Onuma Y, Serruys PW. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015;8:1715-1726. doi: 10.1016/j. jcin.2015.07.026.
45. Räber L, Brugaletta S, Yamaji K, O'SulliVan CJ, Otsuki S, Koppara T, Taniwaki M, Onuma Y, Freixa X, Eberli FR, Serruys PW, Joner M, Sabaté M, Windecker S. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66:1901-1914. doi: 10.1016/j. jacc.2015.08.853.
46. Stone GW, Granada JF. Very late thrombosis after bioresorbable scaffolds: cause for concern? J Am Coll Cardiol. 2015;66:1915-1917. doi: 10.1016/j.jacc.2015.08.863.
47. Bartorelli AL. Interim report on the 36-month clinical outcomes from the first 500 patients enrolled in the ABSORB EXTEND study. J Am Coll Cardiol. 2015;66(suppl B):B206.
48. Chevalier B, Serruys PW; ABSORB II Investigators. The 2-year clinical outcomes of the ABSORB II trial: first randomized comparison between the Absorb everolimus eluting bioresorbable vascular scaffold and the XIENCE everolimus eluting stent. Paper presented at: TCT 2015; October 12, 2015; San Francisco, CA.
49. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimuseluting scaffold in patients with de novo coronary artery disease: the ABSORB Cohort A trial. JACC Cardiovasc Interv. 2013;6:999-1009. doi: 10.1016/j.jcin.2013.05.017.
50. Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A, Brugaletta S, Hofma SH, Räber L, Christiansen EH, Suttorp M, Pilgrim T, Anne Van Es G, Sotomi Y, Garciá-Garciá HM, Onuma Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37:229-240. doi: 10.1093/eurheartj/ehv500.
51. Ko?ka V, Lisa L, Toušek P, Bud?šínský T, Widimský P. ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. Eur Heart J. 2013;34:2073. doi: 10.1093/eurheartj/eht168.
52. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014;7:89-99. doi: 10.1016/j.jcin.2013.07.007.
53. Ormiston JA, Webber B, Ubod B, Darremont O, Webster MW. An independent bench comparison of two bioresorbable drugeluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015;11:60-67. doi: 10.4244/EIJY15M02-03.
54. Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, Botelho RV, Costa JR Jr, Chamié D, Abizaid AS, Castro JP, Morrison L, Toyloy S, Bhat V, Yan J, Verheye S. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc Interv. 2016;9:565-574. doi: 10.1016/j.jcin.2015.12.004.
55. Wiebe J, Bauer T, Dörr O, Möllmann H, Hamm CW, Nef HM. Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 ?m showing evidence of self-correction. EuroIntervention. 2015;11:204. doi: 10.4244/EIJY15M02-01.
56. Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, Ilsley C, Di Mario C, Erbel R, Waksman R, Dalby M. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention. 2009;4:481-484.
57. Eggebrecht H, Rodermann J, Hunold P, Schmermund A, Böse D, Haude M, Erbel R. Images in cardiovascular medicine: novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation. 2005;112:e303-e304. doi: 10.1161/01.CIRCULATIONAHA.104.521641.